Johnson & Johnson at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 12:50PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD

Great. Well, great. Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs. And we're very pleased to have Johnson & Johnson with us. Joining us from the company this morning is Mathai Mammen, who is Global Head of R&D. Mathai, thank you so much for joining us. I really appreciate your time today.

Mathai Mammen - Johnson & Johnson - Global Head of Research & Development of Janssen Pharmaceutical

It's my great pleasure, Terence. Happy to be here.

Questions and Answers:

Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD

Great. Maybe just to start a couple of high-level questions. The first one I had is just as you think about your capabilities on the R&D side, what do you think really differentiates J&J's approach? And again, as we think about kind of the implications of COVID, any changes to R&D that you're making as a result coming out of the
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot